LIXTE Biotechnology Acquires NOMAD Transportable Power Systems in Strategic Pivot Away from Pharma

A NASDAQ-listed biotech is exiting the pharmaceutical sector entirely: LIXTE Biotechnology Holdings, Inc. (LIXT) has entered a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, Inc., a Vermont-based manufacturer of deployable, utility-grade battery energy storage systems. Upon closing, LIXTE will be renamed NOMAD Power Solutions, marking a full strategic pivot away from drug development.

For pharma industry observers, the transaction is a signal of capital reallocation at the small-cap biotech tier. LIXTE's decision to dissolve its pharmaceutical identity in favour of energy infrastructure reflects the pressure facing early-stage biotechs with limited pipeline commercialisation timelines. The deal does not involve any transfer of drug assets, IND portfolios, or GMP manufacturing infrastructure.

NOMAD's core product is a mobile, utility-grade 1 MW battery energy storage system, validated to UL 9540 full-system standards and compliant with NFPA 855 and IEEE 1547 interconnection requirements. The company reports revenue growth of approximately 175% year-over-year in 2025, with management projecting approximately 135% growth in 2026. Roughly 75% of sales activity is described as inbound, with more than 30 active customer opportunities across North American utility, infrastructure, and industrial segments.

The structural rationale centres on permitting speed. Permanent battery storage projects in the United States face development timelines of two to five years, constrained by land use entitlements, environmental review under NEPA and CEQA, and interconnection queues currently holding approximately 2.3 terawatts of generation and storage capacity. NOMAD's transportable architecture is deployed as equipment rather than permanent infrastructure, which management states generally bypasses those regulatory pathways. In New York State alone, 108 local jurisdictions have enacted moratoria or outright bans on permanent BESS installations, sidelining approximately 1 GW of planned capacity.

No financial terms of the acquisition were disclosed in the announcement. The closing timeline and any regulatory conditions precedent have not been detailed in available materials.

The transaction's completion will effectively remove LIXTE from the pharmaceutical and biotech investment universe, with the combined entity's performance thereafter tied to energy infrastructure deployment metrics rather than clinical or regulatory milestones.

Source: LIXTE Biotechnology Holdings, Inc. press release via GlobeNewswire, June 12, 2026.